This study focuses on women with breast cancer that is hormone receptor-positive (ER+) and HER2-negative, who have completed their initial treatment but have a high risk of the cancer returning. The study examines whether adding a medication called everolimus (Afinitor) to standard hormone therapy can help prevent the cancer from coming back.
The medication being tested, everolimus, is taken as tablets by mouth along with regular hormone therapy. Some participants will receive everolimus tablets while others will receive placebo tablets. The treatment continues for 2 years, during which time participants take their assigned medication in addition to their standard hormone therapy.
The main goal of this research is to determine if adding everolimus to standard hormone treatment helps keep patients cancer-free for a longer time. Throughout the study, doctors will monitor participants’ health and track whether the cancer returns. The study will also look at how well patients tolerate the treatment combination and its effects on their overall health.
Belgium 
France 
